This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Gareth Carpenter
30 Jul 2021

CPHI Trend Report - CDMO Opportunities in the Chinese Market

Opportunities for contract development and manufacturing organisations (CDMOs) in China continue to grow but many questions remain over what the future of the sector will look like in the world's second largest pharmaceutical market.

At present, there are three main areas driving CDMO opportunities in China: the recent rapid transformation of the country's healthcare sector, recent changes to its Drug Administration Law, and Chinese pharma companies' desire to tap into international markets.

CDMOs can be the logical bridge to this aspiration, given their expertise and experience in bringing products to the global market, where prices are often much more attractive than those in the Chinese domestic market.

Change is afoot in China, and via interviews with industry experts from BioPlan Associates, Biovane, Lonza and Vetter, this CPHI Trend Report seeks to explain how recent regulatory reform has impacted the pharmaceutical and biopharmaceutical contract services sector in the country and whether the government’s newfound emphasis on innovative products will transform how CDMOs are perceived in this complex but potentially lucrative market.

Mentioned Companies
View company profile
View company profile
Vetter Pharma-Fertigung GmbH & Co. KG
View company profile
Gareth Carpenter

Related News